Biofrontera Q2 Revenue Jumps 33%, Nears Breakeven Ahead of Key FDA Decision
BFRI has more than doubled off its 52-week low of $0.555.
Summary
Biofrontera delivered its strongest standalone quarter yet: Q2 revenue rose 33% to $12.0M, driven by higher volume and pricing, gross margin expanded to 80% from 71%, and net loss narrowed to just $0.6M from $5.3M a year ago. Adjusted EBITDA came in at $(0.2)M, nearly breakeven, and operating cash burn fell 76% in the first half. The company also flagged a PDUFA date in late September for Ameluz in superficial basal cell carcinoma, which would be the first PDT approved for cancerous tumors in the U.S. This follows the strategic transaction with Biofrontera AG that reset the cost structure. The ITC exclusion order on the RhodoLED XL lamp pulled some orders into Q2, but management says full-year revenue goals remain intact. With the stock trading near its 52-week high, this print validates the turnaround and sets up a binary FDA catalyst within weeks.
At the time of this announcement, BFRI was trading at $1.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $16M. The 52-week trading range was $0.55 to $1.27. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.